secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0001558370-25-009186
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor receives FDA Complete Response Letter for Deramiocel BLA; plans Q3 2025 resubmission with HOPE-3 data
--------------------------------------------------------------------------------

- FDA issued CRL stating BLA lacks substantial evidence of effectiveness; additional clinical data needed.
- Capricor plans to resubmit BLA in Q3 2025 with data from ongoing Phase 3 HOPE-3 trial (104 patients, topline Q3 2025).
- FDA confirmed review clock restarts upon resubmission; Type A meeting offered to discuss path forward.
- CRL referenced outstanding CMC items, but Capricor believes most were addressed; not reviewed due to CRL timing.
- Prior to CRL, BLA had Priority Review, successful pre-licensure inspection, and mid-cycle review completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837025009186/0001558370-25-009186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837025009186/capr-20250711x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-009186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer